Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aska Pharmaceutical Signs License With Sosei On Emergency Contraception Drug

This article was originally published in PharmAsia News

Executive Summary

Aska Pharmaceutical signed a license agreement with Sosei Oct. 21 and obtained exclusive rights to market SOH-075, an emergency contraception pill Sosei in-licensed from French Laboratoire HRA Pharma. SOH-075 completed Phase III trials in Japan and an approval is expected by the early half of 2009. According to the agreement, Sosei will receive a ¥300 million upfront payment, as well as potential milestone and royalty payments. Sosei will apply for the new drug approval and Aska will market the drug and conduct post-market surveillance. (Click here for more - Japanese language
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC066986

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel